PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development

Background: The M72/AS01E tuberculosis vaccine candidate, currently on trial in Indonesia, includes PPE18 (Rv1196) and PepA (Rv0125) as key antigens. Genetic variation in these proteins may affect immune recognition and vaccine efficacy. This study aims to analyse the genetic diversity of Rv1196 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephanie Cynthia Theorupun, Muhammad Nasrum Massi, Astutiati Nurhasanah, Fadhilah Syamsuri, Mochammad Hatta, Yoeke Dewi Rasita, Najdah Hidayah, Nihayatul Karimah, Doddy Irawan Setyo Utomo
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-04-01
Series:International Journal of Mycobacteriology
Subjects:
Online Access:https://journals.lww.com/10.4103/ijmy.ijmy_70_25
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850083121852055552
author Stephanie Cynthia Theorupun
Muhammad Nasrum Massi
Astutiati Nurhasanah
Fadhilah Syamsuri
Mochammad Hatta
Yoeke Dewi Rasita
Najdah Hidayah
Nihayatul Karimah
Doddy Irawan Setyo Utomo
author_facet Stephanie Cynthia Theorupun
Muhammad Nasrum Massi
Astutiati Nurhasanah
Fadhilah Syamsuri
Mochammad Hatta
Yoeke Dewi Rasita
Najdah Hidayah
Nihayatul Karimah
Doddy Irawan Setyo Utomo
author_sort Stephanie Cynthia Theorupun
collection DOAJ
description Background: The M72/AS01E tuberculosis vaccine candidate, currently on trial in Indonesia, includes PPE18 (Rv1196) and PepA (Rv0125) as key antigens. Genetic variation in these proteins may affect immune recognition and vaccine efficacy. This study aims to analyse the genetic diversity of Rv1196 and Rv0125 in Mycobacterium tuberculosis clinical isolates from Indonesia and assess the structural and immunological implications using in silico methods. Methods: Rv1196 and Rv0125 genes from clinical isolates were sequenced and analysed for polymorphisms. PPE18 variants were modelled using I-TASSER (Iterative Threading ASSEmbly Refinement), and structural stability and HLA (Human Leukocyte Antigen) binding predictions (HLA-I and HLA-II) were performed using IEDB (Immune Epitope Database) tools. Molecular docking with TLR2 (Toll-like Receptor 2) was conducted to evaluate receptor interactions. Results: A novel non-synonymous mutation (T22G, Ser8Ala) was identified in Rv0125, which was otherwise conserved. Rv1196 showed high variability with 58 polymorphic sites, including 38 non-synonymous mutations, a frequent Arg287Gln substitution, and a ΔThr163-Ala164 deletion. Structural modelling indicated preserved PPE18 fold but altered epitope binding in an allele-specific manner. Docking showed stronger TLR2 interactions for variants 6S31 and 6S32, suggesting enhanced IL-10 induction and a Th2-skewed immune response. Conclusions: PPE18 genetic variation may influence immune recognition and the effectiveness of M72/AS01E. Ongoing antigenic surveillance in endemic areas is essential to guide vaccine design and diagnostics.
format Article
id doaj-art-87b3a3235717419fa1bd3b9d2dfe0a7a
institution DOAJ
issn 2212-5531
2212-554X
language English
publishDate 2025-04-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series International Journal of Mycobacteriology
spelling doaj-art-87b3a3235717419fa1bd3b9d2dfe0a7a2025-08-20T02:44:22ZengWolters Kluwer Medknow PublicationsInternational Journal of Mycobacteriology2212-55312212-554X2025-04-0114219120010.4103/ijmy.ijmy_70_25PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine DevelopmentStephanie Cynthia TheorupunMuhammad Nasrum MassiAstutiati NurhasanahFadhilah SyamsuriMochammad HattaYoeke Dewi RasitaNajdah HidayahNihayatul KarimahDoddy Irawan Setyo UtomoBackground: The M72/AS01E tuberculosis vaccine candidate, currently on trial in Indonesia, includes PPE18 (Rv1196) and PepA (Rv0125) as key antigens. Genetic variation in these proteins may affect immune recognition and vaccine efficacy. This study aims to analyse the genetic diversity of Rv1196 and Rv0125 in Mycobacterium tuberculosis clinical isolates from Indonesia and assess the structural and immunological implications using in silico methods. Methods: Rv1196 and Rv0125 genes from clinical isolates were sequenced and analysed for polymorphisms. PPE18 variants were modelled using I-TASSER (Iterative Threading ASSEmbly Refinement), and structural stability and HLA (Human Leukocyte Antigen) binding predictions (HLA-I and HLA-II) were performed using IEDB (Immune Epitope Database) tools. Molecular docking with TLR2 (Toll-like Receptor 2) was conducted to evaluate receptor interactions. Results: A novel non-synonymous mutation (T22G, Ser8Ala) was identified in Rv0125, which was otherwise conserved. Rv1196 showed high variability with 58 polymorphic sites, including 38 non-synonymous mutations, a frequent Arg287Gln substitution, and a ΔThr163-Ala164 deletion. Structural modelling indicated preserved PPE18 fold but altered epitope binding in an allele-specific manner. Docking showed stronger TLR2 interactions for variants 6S31 and 6S32, suggesting enhanced IL-10 induction and a Th2-skewed immune response. Conclusions: PPE18 genetic variation may influence immune recognition and the effectiveness of M72/AS01E. Ongoing antigenic surveillance in endemic areas is essential to guide vaccine design and diagnostics.https://journals.lww.com/10.4103/ijmy.ijmy_70_25antigenmycobacterium tuberculosispepapolymorphismppe18rv0125rv1196vaccine candidate
spellingShingle Stephanie Cynthia Theorupun
Muhammad Nasrum Massi
Astutiati Nurhasanah
Fadhilah Syamsuri
Mochammad Hatta
Yoeke Dewi Rasita
Najdah Hidayah
Nihayatul Karimah
Doddy Irawan Setyo Utomo
PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
International Journal of Mycobacteriology
antigen
mycobacterium tuberculosis
pepa
polymorphism
ppe18
rv0125
rv1196
vaccine candidate
title PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
title_full PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
title_fullStr PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
title_full_unstemmed PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
title_short PPE18 and PepA Variations in Mycobacterium tuberculosis Clinical Isolates from Makassar, Indonesia: Challenges for Immune Recognition and Vaccine Development
title_sort ppe18 and pepa variations in mycobacterium tuberculosis clinical isolates from makassar indonesia challenges for immune recognition and vaccine development
topic antigen
mycobacterium tuberculosis
pepa
polymorphism
ppe18
rv0125
rv1196
vaccine candidate
url https://journals.lww.com/10.4103/ijmy.ijmy_70_25
work_keys_str_mv AT stephaniecynthiatheorupun ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT muhammadnasrummassi ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT astutiatinurhasanah ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT fadhilahsyamsuri ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT mochammadhatta ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT yoekedewirasita ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT najdahhidayah ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT nihayatulkarimah ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment
AT doddyirawansetyoutomo ppe18andpepavariationsinmycobacteriumtuberculosisclinicalisolatesfrommakassarindonesiachallengesforimmunerecognitionandvaccinedevelopment